Furthermore, following the very recent approval of lecanemab in the European Union, it should be appropriate to evaluate how a real-world cohort aligns with the full treatment indication outlined in the Summary of the Product Characteristics (“adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (Early Alzheimer’s disease) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes with confirmed amyloid pathology”). The gene discussed is APOE; the disease is Cognitive impairment.